With the acquisition of Cell Genesys Inc., Genzyme Corp. might be seen as positioned to further consolidate gene therapy businesses and technology under its multi-division umbrella. But even if it stands pat, Genzyme feels that it has a clear path to commercialize its gene therapy products.

"Gene therapy is one of those programs in a phase like monoclonal antibodies was in not long ago," said Henri Termeer, chairman and CEO. "We do not see today early commercialization of gene therapy products, but the number of gene therapy products in clinical trials is increasing."